The monoamine theory of depression as a target to effective pharmacotherapy
Data publikacji: 30 cze 2023
Zakres stron: 108 - 113
Otrzymano: 29 mar 2023
Przyjęty: 07 cze 2023
DOI: https://doi.org/10.2478/cipms-2023-0019
Słowa kluczowe
© 2023 Tomasz Karabin et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Depression is one of the greatest current mental disorders. Depressive disorder may affect everyone and it causes difficulties in social functioning and may lead to death via suicide. Depression is a serious problem because number of its cases is increasing, especially after pandemic of COVID-19. The oldest and the most approved theory which explains mechanism of depression’s development is a monoamine hypothesis. Effectiveness of most antidepressant drugs based on this theory. It assumes that the typical symptoms of depression are results of changed concentration of monoamines or incorrect monoaminergic transmission. The aim of this article is to present drugs which have influence on level of biogenic amines and are used in treatment of depressive disorders. Some of those drugs are the first choice in cure of this disease. In spite of adverse effects and often delayed onset of action of pharmacotherapy, it is still the first line in treatment of depression.